However, gastrointestinal side effects were observed and several participants discontinued treatment due to diarrhea making the usefulness of DGAT1 inhibition as a novel treatment for diabetes and obesity questionable (81). This evidence concerns the gene DGAT1 and obesity due to melanocortin 4 receptor deficiency.